Compare Amphastar Pharmaceuticals Inc (AMPH) vs Trade Desk Inc (TTD) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

The Trade Desk (TTD) trades at $19.53, down 1.11% with bearish technical signals despite strong profitability metrics including 77.83% gross margins and 14.57% net income margin. Recent earnings show mixed results with Q1 2026 missing expectations, while revenue growth has slowed from 2024's peak. The stock faces headwinds from market share competition and a recent 52% decline in H1 2026, though analyst consensus remains positive with a $25.46 price target representing 30% upside potential.

TTD presents a value opportunity with attractive valuation multiples (P/E 22.19, P/S 3.2) and robust cash flow generation, but investors face execution risks amid slowing growth and competitive pressures. The resolution of the Publicis dispute removes a key overhang, though the stock requires sustained earnings beats and market share stabilization to justify analyst optimism.